9
views
0
recommends
+1 Recommend
2 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Impact of the COVID-19 pandemic on the symptomatic diagnosis of cancer: the view from primary care

      discussion

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The entire landscape of cancer management in primary care, from case identification to the management of people living with and beyond cancer, is evolving rapidly in the face of the coronavirus disease 2019 (COVID-19) pandemic. 1 In a climate of fear and mandated avoidance of all but essential clinical services, delays in patient, population, and health-care system responses to suspected cancer symptoms seem inevitable. Screening, case identification, and referral in symptomatic cancer diagnosis have all been affected by the COVID-19 pandemic. UK national cancer screening programmes—accounting for approximately 5% of all cancer diagnoses each year—have been suspended. 2 Consequently, early diagnoses from screening will be delayed and symptom-based diagnosis of cancer will become more important. 3 Unfortunately, postponing screening sends a message to the public and primary care that cancer can wait. Timely presentation to primary care of patients with symptoms is driven by a combination of appraising symptoms as warranting attention, perceived or actual ability to consult a health-care professional, perceived consequences of seeking help, and priority over competing goals. 4 It is probable that patients with well recognised red flag symptoms, such as a new lump or rectal bleeding, will continue to present to primary care. With COVID-19 at the forefront, however, vague cancer symptoms such as fatigue, change in bowel habit, and weight loss might be dismissed by the patient as trivial. 5 Respiratory symptoms, including persistent cough, might be attributed to COVID-19 and not acted on. Patients might be reluctant to present because of fear of interacting with others, limited capacity to use video or teleconsultations, and concerns about wasting the doctor's time.6, 7 For family doctors, the COVID-19 pandemic is affecting all aspects of normal working life, including a reduced workforce due to illness and self-isolation, and the reduced availability of appointments and investigations in primary and secondary care. The huge shift to telephone triage and video consultations might result in missed cues, reduced examination findings, and loss of the clinician's gut feeling. Remote consulting might also be less suited to vulnerable patients and individuals from low socioeconomic backgrounds than to patients from high socioeconomic settings, compounding inequalities already apparent in early cancer diagnosis. 8 If patients with cancer symptoms do present to primary care, there is no consensus on how they should be managed during the pandemic, or safety-netted. When patients are referred, they are likely to be triaged or delayed. 9 For example, the cancellation of all but emergency endoscopy will inevitably prolong the time to diagnosis of gastrointestinal cancers. Management and follow-up of patients with cancer is also affected by the COVID-19 pandemic. Many patients with cancer, especially those undergoing chemotherapy, radical radiotherapy, and immunotherapy, are at greater risk from the symptoms and sequelae of COVID-19. The National Health Service guidelines state that patients will want to discuss whether the benefits of continuing active cancer treatment outweigh the risks of potentially being seriously unwell if they contract COVID-19, which is a role that could well fall to primary care. 9 The UK cancer charity Macmillan Cancer Support reports that a quarter of calls to its support line are from patients with cancer who are anxious about COVID-19. 10 Although cancer charities provide a vital support role, primary care needs to support the physical and mental health of patients for whom potentially lifesaving cancer treatments are being postponed. Cancer treatments are a priority in the health-care system, but as health-care become increasingly occupied with caring for patients with COVID-19, these patients will inevitably take precedence. Patients needing immediate care are receiving treatment, but when possible, treatments will be delayed. Guidance to help make these difficult decisions might be variable, inconsistent, and hurried, with the inevitable risk to patient outcomes. In this situation, the psychological effect on patients and clinical staff will be enormous. The COVID-19 pandemic has implications for primary care and the crisis has highlighted potential solutions for dealing with future global health threats. Although these are unprecedented times, it is probable that the use of remote consultations will grow. Increased flexibility in accessing health care might serve to advantage some population groups, but risks disadvantaging others. If done well, remote consulting could benefit previously underserved patient populations (ie, individuals living in remote areas). Behavioural interventions to encourage the timely symptomatic diagnosis of cancer are important. Public awareness campaigns should signal that early help-seeking is welcome and legitimate, and might use social media and community networks that have grown in response to COVID-19. Clinicians should be aware of so-called diagnostic overshadowing from COVID-19 and remember that patients might have markedly delayed presentation already and need additional support navigating the next steps in terms of their referral and safety-netting. If cancer is suspected, clinicians should not be deterred from referring patients urgently because of COVID-19 or other future global health threats. However, health-care professionals might have to accept triage and risk stratification of patients with potentially serious disease. Biomarker and machine-learning approaches might support prioritisation of patients who are at greatest risk, diverting health-care resources towards managing patients who are seriously ill. When patients are diagnosed with cancer, or are living with or beyond cancer, providers of primary care might have to accept enhanced roles in supporting decisions on cancer treatment, palliative care, and advanced planning around resuscitation and preferred places of care. When normal service resumes at a population and health-service level, there will be a huge backlog of patients with potential cancer symptoms needing urgent assessment. Planning for recovery should commence as soon as possible. © 2020 Bacho/shutterstock.com 2020 Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

          Related collections

          Most cited references2

          • Record: found
          • Abstract: found
          • Article: not found

          COVID-19: global consequences for oncology

          As the coronavirus disease 2019 (COVID-19) pandemic escalates and countries struggle to contain the virus, health-care systems are under increasing pressure. Emergency departments and intensive care units are nearing breaking point, and medical resources are being diverted to tackle the crisis. Moreover, conferences are being cancelled, and research trials are grinding to a halt. So what does COVID-19 mean for patients with cancer, their physicians, and the wider oncology discipline? Patients with cancer are a high-risk group in the COVID-19 pandemic. They are already vulnerable to infection because of their underlying illness and often immunosuppressed status, and are at increased risk of developing severe complications from the virus, including intensive care unit admission or even death. Moreover, for those who develop COVID-19, treatment of the disease will be prioritised, and further cancer therapy could be delayed, although such decisions must be made on a patient-by-patient basis and not based only on the early small reports published in the first few weeks of the pandemic. Media reports have described patients with cancer in quarantined cities being unable to travel to appointments or struggling to obtain essential medicines; the risk of interruptions in drug supply chains and consequent shortages will exacerbate this issue. Scheduled operations, some types of cancer treatment, and appointments are being cancelled or postponed to prioritise hospital beds and care for those who are seriously ill with COVID-19. In England, UK, despite the 2020 budget promising several billion pounds of extra NHS funding to help tackle the outbreak, when cases of COVID-19 peak in the coming weeks the NHS will undoubtedly be forced to delay non-urgent treatments and surgeries as resources and personnel are repurposed. Unfortunately, the effects of COVID-19 are not solely limited to the treatment of patients with cancer, but will also hit the wider oncology community, with inevitable consequences for research, education, and collaboration. University campuses in the worst hit countries have shut down, with many others expected to follow. Some of those affected, including the University of Bologna, Italy, have responded by digitising their teaching programmes, moving classes and exams online to alleviate the educational impact. However, such solutions cannot be used for practical laboratory work or field studies, and ongoing research projects are being jeopardised. Limited resources and capacity will force institutions to decide which clinical trials to prioritise and which to suspend. Many institutions, including the Dana Farber Cancer Institute (Boston, MA, USA) are restricting employees’ work-related travel, and others such as the Fred Hutchinson Cancer Research Center (Seattle, WA, USA—one of the worst-affected US cities) are implementing mandatory work from home policies. However, not all centres in affected regions have similar policies, and such heterogeneity might create imbalances in patient cohorts in multicentre trials, potentially biasing eventual results. With some governments advising against or banning non-essential travel and large-scale events, at least eight major cancer meetings and conferences have been cancelled or postponed, with many more expected to follow. As a result, innumerable opportunities for discussion and collaboration will be lost, the latest research will not be presented, and patients will subsequently be affected by the delay in dissemination of information on the latest treatment to their doctors. Although some congresses are being reorganised to take place online, face-to-face meetings are a crucial aspect of team science and cannot be eliminated completely. Furthermore, societies and organisations postponing or cancelling meetings will probably face financial consequences that could have long-term effects on their ability to fund key activities in the future. The American Society of Clinical Oncology—which at the time of writing had not yet decided about their 2020 annual meeting—relied on a huge US$43 million in revenue from education and meeting registration fees in 2018. For smaller societies that rely on their annual meetings financially, cancellations could threaten their existence. With the situation constantly changing, all we can do for now is watch, wait, and adapt as best we can until the immediate and long-term effects of this pandemic fully materialise. Ultimately, the situation might lead to substantial changes in how research and medicine are practiced in the future, such as reduced international travel and increased remote networking and telemedicine. Until the COVID-19 pandemic is over, we can only hope that the consequences are not too devastating for patients and that the oncology community and beyond are able to weather this unprecedented storm. © 2020 CDC/Science Photo Library 2020 Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Covid-19 and long term conditions: what if you have cancer, diabetes, or chronic kidney disease?

              Bookmark

              Author and article information

              Contributors
              Journal
              Lancet Oncol
              Lancet Oncol
              The Lancet. Oncology
              Elsevier Ltd.
              1470-2045
              1474-5488
              30 April 2020
              30 April 2020
              Affiliations
              [a ]Leeds Institute of Health Sciences, University of Leeds, Leeds LS2 9NL, UK
              [b ]West Yorkshire and Harrogate Cancer Alliance, White Rose House, Wakefield, UK
              [c ]Faculty of Dentistry, Oral and Craniofacial Sciences, King's College London, Guy's Hospital, London, UK
              [d ]School of Health Sciences, University of Surrey, Surrey, UK
              [e ]Division of Population Medicine, College of Biomedical and Life Sciences, Cardiff University, Cardiff, UK
              Article
              S1470-2045(20)30242-4
              10.1016/S1470-2045(20)30242-4
              7251992
              32359404
              c40a3f5c-e6bc-4970-affb-97ad69063124
              © 2020 Elsevier Ltd. All rights reserved.

              Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

              History
              Categories
              Article

              Oncology & Radiotherapy
              Oncology & Radiotherapy

              Comments

              Comment on this article